OCULAR THERAPEUTIX INC (OCUL) Stock Price, Quote, News and Overview
NASDAQ:OCUL - Nasdaq - US67576A1007 - Common Stock - Currency: USD
OCUL Quote, Performance and Key Statistics
7
-0.25 (-3.45%)
The current stock price of OCUL is 7 USD. In the past month the price decreased by -12.28%. In the past year, price decreased by -29.01%.
OCUL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About OCUL
Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 267 full-time employees. The company went IPO on 2014-07-25. The firm is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. The company is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. The company is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).
Company Info
OCULAR THERAPEUTIX INC
15 Crosby Drive
Bedford MASSACHUSETTS 01730 US
CEO: Antony Mattessich
Employees: 267
Company Website: https://www.ocutx.com/
Investor Relations: https://ocutx.gcs-web.com/
Phone: 17813574000
OCULAR THERAPEUTIX INC / OCUL FAQ
What is the stock price of OCULAR THERAPEUTIX INC today?
The current stock price of OCUL is 7 USD. The price decreased by -3.45% in the last trading session.
What is the ticker symbol for OCULAR THERAPEUTIX INC stock?
The exchange symbol of OCULAR THERAPEUTIX INC is OCUL and it is listed on the Nasdaq exchange.
On which exchange is OCUL stock listed?
OCUL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for OCULAR THERAPEUTIX INC stock?
15 analysts have analysed OCUL and the average price target is 18.59 USD. This implies a price increase of 165.52% is expected in the next year compared to the current price of 7. Check the OCULAR THERAPEUTIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OCULAR THERAPEUTIX INC worth?
OCULAR THERAPEUTIX INC (OCUL) has a market capitalization of 1.10B USD. This makes OCUL a Small Cap stock.
How many employees does OCULAR THERAPEUTIX INC have?
OCULAR THERAPEUTIX INC (OCUL) currently has 267 employees.
What are the support and resistance levels for OCULAR THERAPEUTIX INC (OCUL) stock?
OCULAR THERAPEUTIX INC (OCUL) has a support level at 6.99 and a resistance level at 7.49. Check the full technical report for a detailed analysis of OCUL support and resistance levels.
Is OCULAR THERAPEUTIX INC (OCUL) expected to grow?
The Revenue of OCULAR THERAPEUTIX INC (OCUL) is expected to grow by 7.42% in the next year. Check the estimates tab for more information on the OCUL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OCULAR THERAPEUTIX INC (OCUL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OCUL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OCUL, evaluating the profitability, health, valuation and growth aspects
- OCULAR THERAPEUTIX INC (OCUL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OCULAR THERAPEUTIX INC (OCUL) Sales and EPS estimates to see what analysts future expectations are.
- OCULAR THERAPEUTIX INC (OCUL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OCULAR THERAPEUTIX INC (OCUL) Insider and Institutional Ownership to learn about the owners and their transactions.
- OCULAR THERAPEUTIX INC (OCUL) Stock Chart to make your own analysis
- OCULAR THERAPEUTIX INC (OCUL) Latest news and press-releases to stay up to date.
Does OCULAR THERAPEUTIX INC (OCUL) stock pay dividends?
OCUL does not pay a dividend.
When does OCULAR THERAPEUTIX INC (OCUL) report earnings?
OCULAR THERAPEUTIX INC (OCUL) will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of OCULAR THERAPEUTIX INC (OCUL)?
OCULAR THERAPEUTIX INC (OCUL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
What is the Short Interest ratio of OCULAR THERAPEUTIX INC (OCUL) stock?
The outstanding short interest for OCULAR THERAPEUTIX INC (OCUL) is 7.18% of its float. Check the ownership tab for more information on the OCUL short interest.
OCUL Technical Analysis
OCUL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OCUL. The financial health of OCUL is average, but there are quite some concerns on its profitability.
OCUL Financial Highlights
Over the last trailing twelve months OCUL reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS decreased by -44.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.55% | ||
| ROE | -49.52% | ||
| Debt/Equity | 0.19 |
OCUL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to OCUL. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -2.38% and a revenue growth 7.42% for OCUL